Title 40 published on 2015-07-01 .
No entries appear in the Federal Register after this date, for 40 CFR Part 266.
This is a list of United States Code sections, Statutes at Large, Public Laws, and Presidential Documents, which provide rulemaking authority for this CFR Part.
This list is taken from the Parallel Table of Authorities and Rules provided by GPO [Government Printing Office] .
It is not guaranteed to be accurate or up-to-date, though we do refresh the database weekly. More limitations on accuracy are described at the GPO site.
United States Code U.S. Code: Title 42 - THE PUBLIC HEALTH AND WELFARE § 1006 - Applications and furnishing of information
§ 2002 - Transfer of hospitals and facilities to State or private institutions; conditions and restrictions; failure to meet requirements
§ 3001 - Congressional declaration of objectives
§ 3009
§ 3014 - Repealed. Pub. L. 97–115, § 2(e)(1), Dec. 29, 1981, 95 Stat. 1596
§ 3017 - Evaluation of programs
§ 6905 - Application of chapter and integration with other Acts
§ 6906 - Financial disclosure
§ 6912 - Authorities of Administrator
§ 6921 - Identification and listing of hazardous waste
§ 6922 - Standards applicable to generators of hazardous waste
§ 6924 - Standards applicable to owners and operators of hazardous waste treatment, storage, and disposal facilities
§ 6925 - Permits for treatment, storage, or disposal of hazardous waste
§ 6926 - Authorized State hazardous waste programs
§ 6927 - Inspections
§ 6934 - Monitoring, analysis, and testing
§ 6937 - Inventory of Federal agency hazardous waste facilities
Title 40 published on 2015-07-01
The following are ALL rules, proposed rules, and notices (chronologically) published in the Federal Register relating to 40 CFR Part 266 after this date.
2015-11-05; vol. 80 # 214 - Thursday, November 5, 2015 80 FR 68491 - Management Standards for Hazardous Waste Pharmaceuticals
GPO FDSys XML | Text Additional Documents ENVIRONMENTAL PROTECTION AGENCY Proposed rule; extension of comment period. Comments on the proposed rule published September 25, 2015 (80 FR 58014) must be received on or before December 24, 2015. 40 CFR Parts 261, 262, 266, 268, and 273 Summary The Environmental Protection Agency (EPA or the Agency) is announcing an extension to the comment period for the proposed rule on the management and disposal of hazardous waste pharmaceuticals published in the Federal Register on September 25, 2015. EPA is proposing new hazardous waste pharmaceutical regulations under the Resource Conservation and Recovery Act (RCRA) to improve compliance and thereby enhance protection of human health and the environment. Specifically, EPA proposed to revise the regulations to improve the management and disposal of hazardous waste pharmaceuticals and tailor them to address the specific issues that hospitals, pharmacies and other healthcare-related facilities face. The revisions are also intended to clarify the regulation of the reverse distribution mechanism used by healthcare facilities for the management of unused and/or expired pharmaceuticals. The comment period is being extended to December 24, 2015.
2015-10-19; vol. 80 # 201 - Monday, October 19, 2015 80 FR 63284 - Hazardous Waste Export-Import Revisions
GPO FDSys XML | Text Additional Documents ENVIRONMENTAL PROTECTION AGENCY Proposed rule. Comments must be received on or before December 18, 2015. Under the Paperwork Reduction Act, comments on the information collection provisions are best assured of having full effect if the Office of Management and Budget (OMB) receives a copy of your comments on or before November 18, 2015. 40 CFR Parts 260, 261, 262, 263, 264, 265, 266, 267, 271 and 273 Summary The Environmental Protection Agency (EPA) is proposing to amend our existing regulations in regards to the export and import of hazardous wastes from and into the United States. EPA is proposing these changes to: Provide greater protection to human health and the environment by making existing export and import related requirements more consistent with the current import-export requirements for shipments between members of the Organization for Economic Cooperation and Development (OECD); enable electronic submittal of all export and import-related documents ( e.g., export notices, export annual reports); and enable electronic validation of consent in the Automated Export System (AES) for export shipments subject to RCRA export consent requirements prior to exit.
2015-09-25; vol. 80 # 186 - Friday, September 25, 2015 80 FR 58014 - Management Standards for Hazardous Waste Pharmaceuticals
GPO FDSys XML | Text Additional Documents ENVIRONMENTAL PROTECTION AGENCY Proposed rule. Comments must be received on or before November 24, 2015. 40 CFR Parts 261, 262, 266, 268, and 273 Summary Some pharmaceuticals are regulated as hazardous waste under the Resource Conservation and Recovery Act (RCRA) when discarded. Healthcare facilities that generate hazardous waste pharmaceuticals as well as associated facilities have reported difficulties complying with the Subtitle C hazardous waste regulations for a number of reasons. First, healthcare workers, whose primary focus is to provide care for patients, are not knowledgeable about the RCRA hazardous waste regulations, but are often involved in the implementation of the regulations. Second, a healthcare facility can have thousands of items in its formulary, making it difficult to ascertain which ones are hazardous wastes when disposed. Third, some active pharmaceutical ingredients are listed as acute hazardous wastes, which are regulated in small amounts. To facilitate compliance and to respond to these concerns, the U.S. Environmental Protection Agency (EPA or the Agency) is proposing to revise the regulations to improve the management and disposal of hazardous waste pharmaceuticals and tailor them to address the specific issues that hospitals, pharmacies and other healthcare-related facilities face. The revisions are also intended to clarify the regulation of the reverse distribution mechanism used by healthcare facilities for the management of unused and/or expired pharmaceuticals.
